ABSTRACT RISK MANAGEMENT MODELLING FOR PRODUCT X IN THE PHARMACEUTICAL INDUSTRY Y
In running the business and operational wheels of the company, pharmaceutical manufacturing deals with risks, both internal and external risk that can affect company goals and objectives. To that end, the risk needs to be managed and controlled in order not to give a broad impact for the company....
Saved in:
Main Author: | |
---|---|
Format: | Theses |
Language: | Indonesia |
Online Access: | https://digilib.itb.ac.id/gdl/view/44463 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Institut Teknologi Bandung |
Language: | Indonesia |
Summary: | In running the business and operational wheels of the company, pharmaceutical
manufacturing deals with risks, both internal and external risk that can affect
company goals and objectives. To that end, the risk needs to be managed and
controlled in order not to give a broad impact for the company. In pharmaceutical
manufacturing, any manufactured product will remain at risk even after applying
Good Manufacturing Practice (GMP). Related risks such as risks to safety, quality
and efficacy of the products produced, timely supply of products, risks from raw
material suppliers to regulatory risks and other risks. Zero risk reduction is not a
realistic goal but patient protection by managing these risks in the quality system and
its manufacturing process becomes very important in the pharmaceutical industry.
In general, risk management on a product will facilitate risk management, since each
product has different characteristics and profiles and the risks that will arise will be
different too. In this study, it aims to establish an integrated product risk management
model that can be applied to various risk categories. This research was made by
creating a risk management model, followed by model testing on backbone products
in Y pharmaceutical industry. The test results showed that the Luzar 2017 model
tested was able to identify 459% more risk by generating 93 improvement plans when
compared to the previous model. This suggests that the Luzar 2017 model can be
used for modeling the risk management of X product in the Y pharmaceutical
industry
|
---|